Immunoglobulin G response to mammalian cell entry 1A (Mce1A) protein as biomarker of active tuberculosis

Iukary Takenami1, Carolina C de Oliveira1, Filipe R Lima2

  • 1Laboratório Avançado de Saúde Pública, Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, P.O. Box 121, Salvador, BA 40296 710, Brazil.

Insights

Researchers investigated antibodies against Mycobacterium tuberculosis cell wall protein Mce1A for diagnosing tuberculosis (TB). Elevated immunoglobulin levels (IgA, IgM, IgG) in TB patients suggest Mce1A antibodies can aid in TB diagnosis and treatment monitoring.

Area of Science:

  • Immunology
  • Microbiology
  • Infectious Diseases

Background:

  • Mycobacterium tuberculosis cell wall components are key virulence factors.
  • Mammalian cell entry protein 1A (Mce1A) facilitates pathogen entry into host cells.
  • Immune responses to Mce1A are crucial in tuberculosis pathogenesis.

Purpose of the Study:

  • To evaluate serum immunoglobulin (IgA, IgM, total IgG) levels against Mce1A as potential biomarkers for tuberculosis (TB) diagnosis.
  • To assess the utility of Mce1A antibodies in monitoring TB treatment response.
  • To compare the diagnostic performance of Mce1A antibody detection with routine sputum smear microscopy.

Main Methods:

  • Serum samples from 39 pulmonary TB patients and 65 controls were analyzed using ELISA.
  • Levels of IgA, IgM, and total IgG antibodies against Mce1A were quantified.
  • Diagnostic sensitivity and specificity of antibody detection were calculated and compared to sputum smear results.

Main Results:

  • Significantly higher median levels of IgA, IgM, and total IgG were observed in TB patients compared to all control groups.
  • Positive test results for IgA, IgM, and IgG were 62%, 54%, and 82%, respectively.
  • IgG antibody detection showed a sensitivity of 79.5% and specificity of 84.4%, outperforming sputum smear microscopy (67% sensitivity).
  • A significant decrease in antibody levels post-treatment was noted.

Conclusions:

  • Circulating total IgG antibodies against Mce1A show promise as a complementary diagnostic biomarker for pulmonary TB.
  • Mce1A-specific antibody detection could potentially aid in monitoring treatment response in TB patients.
  • Further validation is warranted to establish Mce1A antibody assays in clinical TB diagnostics.